Royal London Asset Management Ltd. Has $24.83 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Royal London Asset Management Ltd. raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 344,465 shares of the medical equipment provider’s stock after acquiring an additional 9,454 shares during the quarter. Royal London Asset Management Ltd. owned approximately 0.15% of Hologic worth $24,832,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of HOLX. FMR LLC grew its stake in Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after acquiring an additional 2,174,093 shares in the last quarter. Boston Partners grew its stake in shares of Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after buying an additional 1,602,463 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after buying an additional 544,889 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Hologic in the 4th quarter valued at approximately $27,007,000. Finally, Swedbank AB grew its stake in shares of Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after buying an additional 306,562 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.8 %

Shares of HOLX stock opened at $61.47 on Friday. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The firm has a market cap of $13.79 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The stock has a 50 day moving average of $66.06 and a 200-day moving average of $74.05. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Stephens reissued an “overweight” rating and issued a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada lowered their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday, February 6th. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Wolfe Research assumed coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Finally, Raymond James reaffirmed an “outperform” rating and set a $90.00 target price (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.